Literature DB >> 36262691

Therapeutic Potential of miRNAs for Type 2 Diabetes Mellitus: An Overview.

Pads Palihaderu1, Bilm Mendis1, Jmkjk Premarathne2, Wkrr Dias3, Swee Keong Yeap4, Wan Yong Ho5, A S Dissanayake6, I H Rajapakse7, P Karunanayake8, U Senarath9, D A Satharasinghe1.   

Abstract

MicroRNA(miRNA)s have been identified as an emerging class for therapeutic interventions mainly due to their extracellularly stable presence in humans and animals and their potential for horizontal transmission and action. However, treating Type 2 diabetes mellitus using this technology has yet been in a nascent state. MiRNAs play a significant role in the pathogenesis of Type 2 diabetes mellitus establishing the potential for utilizing miRNA-based therapeutic interventions to treat the disease. Recently, the administration of miRNA mimics or antimiRs in-vivo has resulted in positive modulation of glucose and lipid metabolism. Further, several cell culture-based interventions have suggested beta cell regeneration potential in miRNAs. Nevertheless, few such miRNA-based therapeutic approaches have reached the clinical phase. Therefore, future research contributions would identify the possibility of miRNA therapeutics for tackling T2DM. This article briefly reported recent developments on miRNA-based therapeutics for treating Type 2 Diabetes mellitus, associated implications, gaps, and recommendations for future studies.
© The Author(s) 2022.

Entities:  

Keywords:  antimiRs; beta-cell differentiation; metabolism; miRNA; miRNA-mimics; therapeutic

Year:  2022        PMID: 36262691      PMCID: PMC9575458          DOI: 10.1177/25168657221130041

Source DB:  PubMed          Journal:  Epigenet Insights        ISSN: 2516-8657


  108 in total

Review 1.  Developing microRNA therapeutics.

Authors:  Eva van Rooij; Angela L Purcell; Arthur A Levin
Journal:  Circ Res       Date:  2012-02-03       Impact factor: 17.367

2.  Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies.

Authors:  Hongmei Zhu; Siu Wai Leung
Journal:  Diabetologia       Date:  2015-02-13       Impact factor: 10.122

3.  MicroRNA-30d preserves pancreatic islet β-cell function through negative regulation of the JNK signaling pathway via SOCS3 in mice with streptozotocin-induced diabetes mellitus.

Authors:  Shan Wang; Xin Wen; Xin-Rui Han; Yong-Jian Wang; Min Shen; Shao-Hua Fan; Juan Zhuang; Wei Xu; Zi-Feng Zhang; Qun Shan; Meng-Qiu Li; Bin Hu; Chun-Hui Sun; Dong-Mei Wu; Jun Lu; Yuan-Lin Zheng
Journal:  J Cell Physiol       Date:  2018-04-16       Impact factor: 6.384

4.  Role of microRNA-21 in the formation of insulin-producing cells from pancreatic progenitor cells.

Authors:  Chunyu Bai; Xiangchen Li; Yuhua Gao; Kunfu Wang; Yanan Fan; Shuang Zhang; Yuehui Ma; Weijun Guan
Journal:  Biochim Biophys Acta       Date:  2015-12-03

Review 5.  The art of microRNA: various strategies leading to gene silencing via an ancient pathway.

Authors:  Guiliang Tang; Xiaoqing Tang; Venugopal Mendu; Xiaohu Tang; Xiaoyun Jia; Qi-Jun Chen; Liheng He
Journal:  Biochim Biophys Acta       Date:  2008-06-20

6.  Circulating miR-103 family as potential biomarkers for type 2 diabetes through targeting CAV-1 and SFRP4.

Authors:  Mao Luo; Chunrong Xu; Yulin Luo; Gang Wang; Jianbo Wu; Qin Wan
Journal:  Acta Diabetol       Date:  2019-10-03       Impact factor: 4.280

Review 7.  Role of microRNA 21 in diabetes and associated/related diseases.

Authors:  Durairaj Sekar; Basam Venugopal; Punitha Sekar; Krishnan Ramalingam
Journal:  Gene       Date:  2016-01-27       Impact factor: 3.688

8.  MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus.

Authors:  Dwi Setyowati Karolina; Arunmozhiarasi Armugam; Subramaniam Tavintharan; Michael T K Wong; Su Chi Lim; Chee Fang Sum; Kandiah Jeyaseelan
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

Review 9.  Pancreatic regulation of glucose homeostasis.

Authors:  Pia V Röder; Bingbing Wu; Yixian Liu; Weiping Han
Journal:  Exp Mol Med       Date:  2016-03-11       Impact factor: 8.718

10.  Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.

Authors:  Luca F R Gebert; Mario A E Rebhan; Silvia E M Crivelli; Rémy Denzler; Markus Stoffel; Jonathan Hall
Journal:  Nucleic Acids Res       Date:  2013-09-24       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.